# Safety and Efficacy of NNC-0156-0000-0009 After Long-Term Exposure in Patients With Haemophilia B: An Extension to Trials NN7999-3747 and NN7999-3773

> **NCT01395810** · PHASE3 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 71 (actual)

## Conditions studied

- Congenital Bleeding Disorder
- Haemophilia B

## Interventions

- **DRUG:** nonacog beta pegol
- **DRUG:** nonacog beta pegol
- **DRUG:** nonacog beta pegol

## Key facts

- **NCT ID:** NCT01395810
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04-15
- **Primary completion:** 2014-03-30
- **Final completion:** 2014-03-30
- **Target enrollment:** 71 (ACTUAL)
- **Last updated:** 2018-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01395810

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01395810, "Safety and Efficacy of NNC-0156-0000-0009 After Long-Term Exposure in Patients With Haemophilia B: An Extension to Trials NN7999-3747 and NN7999-3773". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01395810. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*